1. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
- Author
-
Patrick J. Kiel, Sherry Williams, Scott Wirth, and Rebecca A. Myers
- Subjects
0301 basic medicine ,business.industry ,Cell ,Myeloid leukemia ,Endogeny ,Enasidenib ,IDH2 ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Isocitrate dehydrogenase ,medicine.anatomical_structure ,Refractory ,Apoptosis ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,business - Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations in isocitrate dehydrogenase (IDH) occur in 20% of AML diagnoses. IDH2 performs a crucial role in cellular metabolism, and when this enzyme is inhibited, the cell cannot rid itself of endogenous products and is thus marked for apoptosis. The US Food and Drug Administration (FDA) approved the first mutant IDH2 inhibitor, enasidenib, for patients with relapsed or refractory IDH2-mutated AML detected by an FDA-approved test.
- Published
- 2018
- Full Text
- View/download PDF